PURPOSE: Patients with gastrointestinal cancer who were receiving moderately emetogenic chemotherapy (MEC) were switched from granisetron, a first-generation 5-hydroxytryptamine-3 receptor antagonist, to palonosetron at our hospital. In the present study, we compared effectiveness before and after switching antiemetic treatment. METHODS: Among patients who were receiving MEC for gastrointestinal cancer, we prospectively observed 46 patients given granisetron and 46 given palonosetron. To allow adverse reactions to be graded in accordance with the Common Terminology Criteria for Adverse Events, version 4.0, a questionnaire designed at our hospital was used to compare the occurrence of delayed nausea and vomiting between patients who received granisetron (GRA group) and those who received palonosetron (PAL group). RESULTS: The incidence of delayed nausea was significantly lower in the PAL group (8.7%, 4/46; p < 0.01) than in the GRA group (37%, 17/46). Delayed vomiting developed in five patients (10.9%) in the GRA group, but did not occur in the PAL group. On the basis of the results of multivariate analysis, young age, female gender, and the use of granisetron were significant risk factors for delayed nausea. CONCLUSION: Our survey showed that palonosetron effectively controls delayed nausea caused by MEC for gastrointestinal cancer.
PURPOSE:Patients with gastrointestinal cancer who were receiving moderately emetogenic chemotherapy (MEC) were switched from granisetron, a first-generation 5-hydroxytryptamine-3 receptor antagonist, to palonosetron at our hospital. In the present study, we compared effectiveness before and after switching antiemetic treatment. METHODS: Among patients who were receiving MEC for gastrointestinal cancer, we prospectively observed 46 patients given granisetron and 46 given palonosetron. To allow adverse reactions to be graded in accordance with the Common Terminology Criteria for Adverse Events, version 4.0, a questionnaire designed at our hospital was used to compare the occurrence of delayed nausea and vomiting between patients who received granisetron (GRA group) and those who received palonosetron (PAL group). RESULTS: The incidence of delayed nausea was significantly lower in the PAL group (8.7%, 4/46; p < 0.01) than in the GRA group (37%, 17/46). Delayed vomiting developed in five patients (10.9%) in the GRA group, but did not occur in the PAL group. On the basis of the results of multivariate analysis, young age, female gender, and the use of granisetron were significant risk factors for delayed nausea. CONCLUSION: Our survey showed that palonosetron effectively controls delayed nausea caused by MEC for gastrointestinal cancer.
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: J Latreille; J Pater; D Johnston; F Laberge; D Stewart; J Rusthoven; P Hoskins; B Findlay; E McMurtrie; L Yelle; C Williams; D Walde; S Ernst; H Dhaliwal; D Warr; F Shepherd; D Mee; L Nishimura; D Osoba; B Zee Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: Tobias Engel Ayer Botrel; Otávio Augusto C Clark; Luciana Clark; Luciano Paladini; Enéas Faleiros; Bruna Pegoretti Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: Ana Carolina Sepúlveda-Vildósola; Yadira Betanzos-Cabrera; Graciela Gascón Lastiri; Hugo Rivera-Márquez; Miguel Angel Villasis-Keever; Volkmar Wanzke Del Angel; Fernando Cerecedo Díaz; Enrique López-Aguilar Journal: Arch Med Res Date: 2008-08 Impact factor: 2.235
Authors: R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro Journal: Ann Oncol Date: 2003-10 Impact factor: 32.976
Authors: Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Hajdenberg; Alan Cartmell; Alberto Macciocchi; Steven Grunberg Journal: Cancer Date: 2003-12-01 Impact factor: 6.860
Authors: Alexander Molassiotis; Peter A Coventry; Carrie T Stricker; Caroline Clements; Beth Eaby; Luke Velders; Cynthia Rittenberg; Richard J Gralla Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612
Authors: Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young Journal: Oncologist Date: 2018-04-12
Authors: Alexandre Chan; Matin M Abdullah; Wan Zamaniah B Wan Ishak; Annielyn B Ong-Cornel; Antonio H Villalon; Ravindran Kanesvaran Journal: J Glob Oncol Date: 2016-11-09